A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.

The urokinase plasminogen activator system is involved in angiogenesis and tumor growth of malignant gliomas, which are highly neovascularized and so may be amenable to antiangiogenic therapy. In this paper, we describe the activity of A6, an octamer capped peptide derived from the non-receptor-binding region of urokinase plasminogen activator. A6 inhibited human microvascular endothelial cell migration but had no effect on the proliferation of human microvascular endothelial cells or U87MG glioma cells in vitro. In contrast, A6 or cisplatin (CDDP) alone suppressed subcutaneous tumor growth in vivo by 48% and 53%, respectively, and, more strikingly, the combination of A6 plus CDDP inhibited tumor growth by 92%. Such combination treatment also greatly reduced the volume of intracranial tumor xenografts and increased survival of tumor-bearing animals when compared with CDDP or A6 alone. Tumors from the combination treatment group had significantly reduced neovascularization, suggesting a mechanism involving A6-mediated inhibition of endothelial cell motility, thereby eliciting vascular sensitivity to CDDP-mediated toxicity. These data suggest that the combination of an angiogenesis inhibitor that targets endothelial cells with a cytotoxic agent may be a useful therapeutic approach.

[1]  M. Dewhirst,et al.  Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. , 2000, Journal of the National Cancer Institute.

[2]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[3]  Charles D. McDermott,et al.  Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  H. Granger,et al.  Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[5]  I. Mizukami,et al.  A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells , 1998, Journal of leukocyte biology.

[6]  P. Opolon,et al.  Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice , 1998, Gene Therapy.

[7]  J. Muscat,et al.  Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. , 1998, Anticancer research.

[8]  W. Cavenee,et al.  Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Preissner,et al.  Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  F. Chiaradonna,et al.  Phosphorylation of Human Pro-Urokinase on Ser138/303 Impairs Its Receptor-dependent Ability to Promote Myelomonocytic Adherence and Motility , 1997, The Journal of cell biology.

[11]  R. Bjerkvig,et al.  Tumor cell invasion and angiogenesis in the central nervous system. , 1997, Current opinion in oncology.

[12]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[13]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[15]  C. Zandonella,et al.  Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. , 1996, Cancer research.

[16]  M. Olman,et al.  Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. , 1995, The American journal of pathology.

[17]  S. Mandriota,et al.  Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[18]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Bruner,et al.  Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. , 1994, Cancer research.

[20]  B. Teicher,et al.  Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents , 1994, International journal of cancer.

[21]  M. Salcman,et al.  Long-term survival in patients with malignant astrocytoma. , 1994, Neurosurgery.

[22]  D. Rifkin,et al.  Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor , 1991, The Journal of cell biology.

[23]  K. Sueishi,et al.  A role of fibrinolytic activity in angiogenesis. Quantitative assay using in vitro method. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[24]  D. Moscatelli,et al.  The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells , 1987, The Journal of cell biology.

[25]  Y. Gursky,et al.  Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains. , 1999, Journal of receptor and signal transduction research.

[26]  B. Teicher,et al.  Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. , 1995, Oncology research.